TARA Protara Therapeutics, Inc.

6d ago, source: Seeking Alpha

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is ...

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

on MSN ago, source:

Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across ...

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

20d ago, source: Business Insider

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

20d ago, source: Business Insider

Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq ...

Protara Therapeutics, Inc. (TARA)

6d ago, source: Yahoo Finance

Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq ...

Protara Therapeutics Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

20d ago, source: Stockhouse

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, ...

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

20d ago, source: Stockhouse

Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), ...

Protara Therapeutics Inc (TARA)

2d ago, source: Investing

On Monday, Oppenheimer has increased the price target on shares of Protera Therapeutics (NASDAQ:TARA) to $30 from the previous $26, while keeping an Outperform rating on the stock.

Protara Therapeutics Inc Ordinary Shares TARA

8d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...